How two giant pharmaceutical companies defrauded the public, flouted government regulations and ignored patient safety in their cutthroat competition.
In this hard-hitting exposé, investigative journalist Sharp (Mr. and Mrs. Hollywood: Edie and Lew Wasserman and Their Entertainment Empire, 2004, etc.) tells the shocking story of how Amgen and Johnson & Johnson partnered to commercially develop a seemingly miraculous anti-anemia drug that would reduce the need for blood transfusions. They conspired to push the drug through the FDA's licensing process without establishing FDA-mandated safety standards while battling ferociously between themselves for market share—secretly selling the product at steep discounts, fraudulently encouraging customers to bill Medicare at full price and using various under-the-table means to give kickbacks to doctors who prescribed the drug. Although the original license specified the drug's use for patients suffering kidney failure, J&J encouraged its use for cancer patients in therapy and started a marketing campaign to encourage doctors to raise the prescribed dosage. Mounting evidence of dangerous side-effects—blood-clotting, rampant spread of cancers and the sudden death of professional athletes who used the drug to enhance their stamina—were disregarded. Sharp artfully weaves in the riveting story of a high-flying salesman at J&J who feared he would be scapegoated for the criminal activities mandated by his bosses. Once rewarded with lavish holidays and other perks, he experienced the dark side of the American Dream when he was fired and blackballed, but he decided to fight back and become a whistle blower. The author unveils how the FDA's regulatory process has been systematically defanged beginning in the mid-1990s when direct TV advertising to the public was allowed. Since then, funding for the agency has decreased and corruption has flourished. A blockbuster of a story, especially today with Medicare potentially on the chopping block.
Pub Date: Sept. 20, 2011
ISBN: 978-0-525-95240-4
Page Count: 434
Publisher: Dutton
Review Posted Online: July 5, 2011
Kirkus Reviews Issue: July 15, 2011
BOOK REVIEW
BOOK REVIEW
Stricter than, say, Bergen Evans or W3 ("disinterested" means impartial — period), Strunk is in the last analysis...
Privately published by Strunk of Cornell in 1918 and revised by his student E. B. White in 1959, that "little book" is back again with more White updatings.
Stricter than, say, Bergen Evans or W3 ("disinterested" means impartial — period), Strunk is in the last analysis (whoops — "A bankrupt expression") a unique guide (which means "without like or equal").Pub Date: May 15, 1972
ISBN: 0205632645
Page Count: 105
Publisher: Macmillan
Review Posted Online: Oct. 28, 2011
Kirkus Reviews Issue: May 1, 1972
This is not the Nutcracker sweet, as passed on by Tchaikovsky and Marius Petipa. No, this is the original Hoffmann tale of 1816, in which the froth of Christmas revelry occasionally parts to let the dark underside of childhood fantasies and fears peek through. The boundaries between dream and reality fade, just as Godfather Drosselmeier, the Nutcracker's creator, is seen as alternately sinister and jolly. And Italian artist Roberto Innocenti gives an errily realistic air to Marie's dreams, in richly detailed illustrations touched by a mysterious light. A beautiful version of this classic tale, which will captivate adults and children alike. (Nutcracker; $35.00; Oct. 28, 1996; 136 pp.; 0-15-100227-4)
Pub Date: Oct. 28, 1996
ISBN: 0-15-100227-4
Page Count: 136
Publisher: Harcourt
Review Posted Online: May 19, 2010
Kirkus Reviews Issue: Aug. 15, 1996
BOOK REVIEW
BOOK REVIEW
© Copyright 2025 Kirkus Media LLC. All Rights Reserved.
Follow
Popular in this Genre
We can’t wait for you to join Kirkus!
It’s free and takes less than 10 seconds!
Already have an account? Log in.
OR
Sign in with GoogleTrouble signing in? Retrieve credentials.
Welcome Back!
OR
Sign in with GoogleTrouble signing in? Retrieve credentials.
